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Abstract 
 
FeNO is the only available point of care test to assess type-2 inflammation in asthma. In making a 
diagnosis of asthma, FeNO should be used together with blood eosinophils and spirometry, alongside a 
history. Raised FeNO in conjunction with blood eosinophilia are treatable traits of type 2 inflammation in 
asthma, which in turn may guide personalised management. A FeNO suppression test can be used to 
assess adherence and device use with ICS therapy. Furthermore FeNO may be used to provide feedback 
to patients in response to ICS, especially when spirometry is normal. FeNO may facilitate appropriate 
referral to secondary care for more definitive specialist investigations. In summary, FeNO is cost 
effective in the diagnosis and management of asthma and should be incorporated into primary care as 
part of routine clinical practice. 
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Introduction 
 
Asthma is characterised by the presence of reversible airway obstruction and airway hyper- 
responsiveness (AHR) usually resulting from type-2 (T2) inflammation1 (Figure 1).  Assessment of asthma 
control is conventionally based on a combination of symptoms, exacerbations, reliever use and 
pulmonary function tests. However, in many patients these parameters are often disconnected from the 
underlying airway inflammatory process
2
. Optimising suppression of T2 inflammation by using sputum 
eosinophils to adjust the inhaled corticosteroid (ICS) dose has shown to reduce frequency of asthma 
exacerbation
3
. Indeed the same has been shown for suppression of AHR
4,5
. However, using induced 
sputum to guide treatment decisions is not feasible for routine clinical practice in either primary or 
secondary care. The fraction of exhaled breath nitric oxide (FeNO) is a well-recognised non- invasive 
point of care surrogate test for T2 airway inflammation
6
. 
Although both FeNO and eosinophils are part of the T2 inflammatory cascade, the two biomarkers are 
regulated by different inflammatory pathways
7-9
. The activation of the T2 inflammatory cascade 
produces a variety of cytokines including interleukin-13 (IL-13) which in turn induces nitric oxide 
synthase in bronchial epithelium
10
. The FeNO level is related to bronchial eosinophilic inflammation
11
 as 
well as to AHR
12
. 
The purpose of the present article is to produce a brief Scottish consensus statement on the role and the 
utility of FeNO in adult asthma. This paper was prepared in collaboration after a meeting of all authors 
to discuss the relevant literature and way forwards on the role of FeNO testing, including in primary 
care, where its use has thus far been minimal.  
FeNO as an aide to asthma diagnosis 
Asthma is a clinical diagnosis, supported where possible by evidence of reversible airflow obstruction 
and/or airway inflammation. As such FeNO alone cannot be used to diagnose asthma. Recent asthma 
guidelines incorporated FeNO (≥ 40ppb) as a starting for the diagnostic algorithm, in conjunction with a 
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comprehensive clinical history suggestive of asthma as well as evidence of airflow obstruction ideally 
using spirometry
13
, or where this is not available in primary care using peak expiratory flow. However, 
elevated FeNO levels may be especially useful at ruling in asthma in patients with a suggestive history 
who have normal spirometry and no bronchodilator response, as reversibility testing with salbutamol is 
only informative in patients with an abnormal FEV1 where there is room for improvement. Hence 
measuring airway calibre using spirometry and T2 inflammation using FeNO could be viewed as being 
relatively disconnected. Pointedly, FeNO has a higher sensitivity and specificity than measuring airway 
calibre using the specialist test impulse oscillometry in distinguishing preschool children with probable 
asthma
14
. The presence of blood eosinophilia (>300 cells/µl) may be used to identify activity of T2 
inflammation, although it may be normal in patients with raised sputum eosinophils. While FeNO alone 
provides sufficient accuracy for detecting T2 inflammation, the combination of FeNO and blood 
eosinophils further improves the strength of identifying T2 related inflammation in asthma
15
. By the same 
token a normal FeNO level in a patient who has stopped pre- existing ICS may be useful for undiagnosing 
asthma, especially when a normal value is obtained in conjunction with a negative bronchial challenge 
test
16
. 
FeNO has a steep dose response curve to budesonide reaching a plateau effect beyond 400µg
17
. On the 
other hand, eosinophilic cationic protein (ECP) a marker of eosinophil activation, reaches a plateau at 
800µg, while AHR requires 1600µg to achieve maximal suppression. Lung function measurement with 
spirometry (FEV1) is rather distant from the underlying T2 inflammation with no further improvement 
above 400µg of budesonide17. Therefore, FeNO stands out as the only available non-invasive point of 
care test that is able to provide an objective assessment of airway inflammation in asthma. 
It is also important to consider the patient’s smoking status when interpreting the results as this can 
suppress FeNO levels
18
. FeNO levels can be elevated for other reasons such as concomitant allergic 
rhinitis
19
 and nasal polyposis
20
. For these reasons, FeNO should be used in conjunction with blood 
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eosinophils and spirometry, alongside a history suggesting asthma. We suggest pragmatic cut off values 
for FeNO of >40ppb and >25ppb to support a diagnosis of asthma in adult patients who are ICS naïve or 
taking ICS respectively. 
FeNO to guide ICS treatment and assess adherence 
 
ICS are the mainstay of treatment for the T2 inflammatory component of persistent asthma. A better 
understanding of T2 inflammation has helped clinicians to personalise asthma treatment, which in turn 
results in improved symptoms, exacerbations and asthma control over and above standard of care. 
Anderson et al.
21
 demonstrated rapid improvements in FeNO with near maximal suppression after 7 
days on fluticasone propionate 100µg/day in steroid-naïve patients. It also took approximately 5 days to 
wash out the effect of ICS, with FeNO returning to baseline after this point. As well as producing dose 
related suppression of FeNO with ICS, the asthma control questionnaire (ACQ) score showed significant 
improvements exceeding the minimal clinically important difference of 0.5 with mean absolute values in 
keeping with optimal control (<0.75)21. In regards to T2 inflammation, a medium dose of ICS suppresses 
both FeNO and blood eosinophils respectively as well as improving AHR22,23. Hence, elevated FeNO may 
be useful to rule in asthma in patients who have stopped their pre-existing ICS. 
Following a month of treatment, fluticasone propionate 200µg/day produced 45% FeNO suppression 
from baseline in moderate persistent asthma, and a 77% reduction in sputum eosinophils, although the 
variability was much higher with the latter
24
. In regards to the effect of medium dose ICS treatment in 
ICS naïve patients, the improvement in ACQ was significant and almost clinically relevant, with mean 
change of 0.49 in patients who had a high FeNO (≥50 ppb) at baseline
25
. As a result of these findings and 
other work a recent meta-analysis
26
 concluded that exacerbations were reduced by 40% in patients 
where FeNO was incorporated into asthma management when compared to standard care. 
Non-adherence to ICS treatment is a common contributing factor to poor asthma control. FeNO has a 
role in monitoring response to ICS and provides an objective clinical point of care test to identify non-
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adherence. McNichol et al.
27
 showed a relatively greater reduction in FeNO in non-adherent patients 
following 7 days of directly observed ICS treatment, as compared to a group of known adherent 
patients. A further study from the same group in severe uncontrolled asthma patients using the 
combination of remote FeNO and electronic inhaler monitoring showed that suppression of FeNO was 
similar after 1 and 4 weeks of ICS treatment , with concomitant suppression of blood eosinophils and 
improvements in FEV1 and ACQ
28
. This ‘FeNO suppression test’ can be therefore used to monitor the 
adherence to ICS, perhaps by bringing patients back to the clinic at regular intervals after educational 
input perhaps along with electronic inhaler monitoring. Moreover, the FeNO suppression test might be 
useful to identify non adherent patients on high dose ICS/LABA before considering expensive treatment 
with biologics. 
FeNO and biologic therapy 
 
With increasing use of biologic therapy in asthma we believe it is important for primary care physicians 
to have a basic understanding of the potential role of FeNO in the management of severe asthma. 
Current asthma guidelines advocate that biologic agents should be considered for poorly controlled 
frequently exacerbating patients including those who require maintenance oral corticosteroids
29-31
. Thus 
it is important to consider which biomarkers can be employed to target T2 inflammation with 
appropriate biologics including anti-IgE (omalizumab), anti-IL 5 (mepolizumab, reslizumab or 
benralizumab) or anti-IL4/13 (dupilumab). In other words can biomarkers including FeNO be used to 
personalise biologic therapy. A key point to bear in mind is that FeNO is mediated by IL-13 signalling 
while eosinophils are mediated by IL-5. 
The EXTRA study
32
 evaluated the additional benefit of omalizumab in reducing future asthma 
exacerbations in uncontrolled severe persistent allergic asthma despite treatment with ICS/LABA. Use of 
omalizumab was associated with 25% relative overall reduction in asthma exacerbations compared to 
placebo
32
. A pre-specified post hoc analysis showed that a greater reduction in asthma exacerbations 
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was seen in the high FeNO group (>19.5 ppb) with a mean reduction of 53% compared to 16% in the low 
FeNO group (<19.5ppb)
32
. Therefore, use of FeNO may help to identify the patients who are likely to 
benefit most from treatment with omalizumab. 
Mepolizumab which blocks IL-5 signalling reduces exacerbations compared to placebo in patients with 
severe eosinophlic asthma despite there being no concomitant effect on FeNO, in keeping with the 
known effects of IL-5 on eosinophils but not FeNO
33
. 
Dupilumab acts by blocking the IL-4 receptor α and hence inhibits signalling of both IL-4 and IL-13, which 
are key drivers of T2 inflammation. Dupilumab was found to optimally reduce exacerbations and 
improve FEV1 in patients who exhibited both FeNO>25ppb and blood eosinophils > 150 cell/ul34. 
Furthermore, dupilumab produced significant reductions in FeNO levels on top of pre-existing medium 
to high dose ICS, in keeping with the known effects of IL-13 on FeNO. Therefore, FeNO is a reliable T2 
biomarker for predicting improvements in airway calibre and reduction in asthma exacerbation 
mediated by blocking IL-4/13. In another study in oral corticosteroid dependent severe asthma, FeNO 
was significantly reduced even in association with tapering down the dose of oral glucocorticoid while 
patients were receiving dupilumab treatment comparing to placebo
35
. 
A randomised placebo-controlled trial that evaluated the effect of anti-IL 13 therapy with tralokinumab
36
 
showed significant reduction in FeNO despite there being no significant reduction on blood, bronchial 
mucosal or sputum eosinophils
36
. This again showed the disconnection between IL-13 mediated effects 
on FeNO and eosinophils. 
Health economics of FeNO 
 
Asthma diagnosis based on FeNO measurement with NIOX MINO is less costly and more accurate than 
standard diagnostic methods. Utilising of FeNO measurement in asthma diagnosis cost £43 less per 
patient as compared with standard diagnostic tests such as spirometry
37
. This resulted in annual cost- 
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savings of £341 and 0.06 quality-adjusted life-years gained for patients with mild to severe asthma and 
£554 and 0.004 quality-adjusted life-years gained for those with moderate to severe asthma
37
. A primary 
care study showed that a FeNO driven strategy for asthma control achieves the highest probability of 
cost effectiveness in terms of willingness to pay to achieve a quality of life adjusted year
38
. 
Conclusions (Box 1) 
 
FeNO is the only non-invasive point of care test to assess type 2 inflammation in asthma. FeNO appears 
to be a cost effective way of making an asthma diagnosis and in achieving better control with ICS 
therapy. FeNO and blood eosinophils should be used together as treatable traits of type 2 inflammation 
in asthma to guide informed management decisions on a personalised basis. The use of FeNO will 
continue to evolve in a primary care setting and will depend on availability and accessibility within 
different regions. A hub and spoke approach linking several practices with a FeNO machine might be a 
cost effective way forward for primary care to more widely adopt this test. 
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Figure legend 
 
Schematic diagram showing the inter-relationship between type-2 (T2) biomarkers, lung function and 
asthma control. 
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Box 1 
 
 
 
 
Panel consensus on utility of FeNO 
  In making a diagnosis of asthma, FeNO should be used in conjunction with blood 
eosinophils and spirometry, alongside a history suggesting asthma. 
  Raised FeNO in conjunction with blood eosinophilia should be regarded as treatable 
traits of type 2 inflammation in asthma, which in turn may be used to guide 
personalised management decisions. 
  ICS should be stopped for at least 1 week in order to obviate a false negative test for 
asthma when using FeNO. 
  We suggest pragmatic cut off values for FeNO of >40ppb and >25ppb to support a 
diagnosis of asthma in adult patients who are ICS naïve or taking ICS respectively. 
  Serial FeNO measures, the so called FeNO suppression test, can be used to help assess 
adherence and device use with ICS therapy. 
  FeNO may be useful as a tool to provide feedback and reassurance to patients in 
response to ICS, especially in cases where spirometry is normal. 
  FeNO may be used to facilitate appropriate referral to secondary care for more 
definitive specialist investigations such as bronchial challenge testing. 
  FeNO is cost effective in the diagnosis and management of asthma and should be 
incorporated into primary care as part of routine clinical practice. 
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Figure 1 
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Highlights: 
• FeNO is the only available point of care test to assess type-2 inflammation in asthma 
• Raised FeNO with blood eosinophilia should be regarded as treatable traits of type 2 
inflammation 
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